# A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

> **NCT00042679** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Pulmonary Neoplasms
- Neoplasms, Lung

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** LY900003

## Key facts

- **NCT ID:** NCT00042679
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2006-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042679, "A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00042679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*